BioLife Corporate Profile

BioLife Logo

Financials

Current Annual Revenue
$15.2 billion

Current Gross Profit
$10.46 billion

Current Annual Net Income
$4.27 billion

2017 Fiscal Year
12.10%


Credit Rating

Moody's Rated: Baa3

 

BioLife Corporate Profile

 

Shire plc, a biotechnology company, focused on serving people with rare diseases and other specialized conditions worldwide. It has collaborative and other licensing arrangements with P zer Inc.; Precision BioSciences; Symphogen; Merrimack Pharmaceuticals, Inc.; Coherus Biosciences, Inc.; Momenta Pharmaceuticals, Inc.; SFJ Pharmaceuticals Group; and Rani erapeutics. Shire plc was founded in 1986 and is based in Dublin, Ireland.